Healthcom

Fobeni Healthcom Pharmaceutical Jiangsu Co., Ltd. (Fobeni Healthcom) is a pharmaceutical joint venture established in 2018 by Shanghai Fosun Pharmaceutical (Group) and Marubeni Corporation. Headquartered in Taizhou, China, the company serves as a strategic bridge for Japanese pharmaceutical firms to introduce innovative therapies into the Chinese market. Fobeni Healthcom is currently advancing the clinical development of nacubactam (OP0595), a novel small molecule beta-lactamase inhibitor being studied in Phase 3 trials for the treatment of complicated urinary tract infections and multi-drug resistant bacterial infections. The company's business model integrates internal R&D focused on antimicrobial resistance with commercial distribution partnerships, such as its collaboration with Kyowa Kirin for the calcimimetic agent Regpara. By leveraging the robust distribution networks and regulatory expertise of its parent companies, Fobeni Healthcom aims to address critical unmet medical needs in infectious diseases and chronic lifestyle conditions.